| Dosaggio del prodotto: 50 mg | |||
|---|---|---|---|
| Confezione (n.) | Per compresse | Prezzo | Acquista |
| 30 | €2.42 | €72.63 (0%) | 🛒 Aggiungi al carrello |
| 60 | €2.02 | €145.25 €121.33 (16%) | 🛒 Aggiungi al carrello |
| 90 | €1.79
Migliore per compresse | €217.88 €161.48 (26%) | 🛒 Aggiungi al carrello |
Prodotti simili
More info:
Popular Products
Enclomisign: A Next-Generation Oral SERD for ER+ Breast Cancer - Evidence-Based Review
Product Description Enclomisign is a novel, non-hormonal, orally administered small molecule therapeutic agent currently under investigation as a selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer. It is designed to overcome limitations of current endocrine therapies, such as acquired resistance to selective estrogen receptor modulators (SERMs) like tamoxifen and degradation-resistant mutations in the estrogen receptor. Unlike traditional SERDs that are often large molecules with poor oral bioavailability (e.
Enclomisign: Stimolazione Endogena del Testosterone per l'Ipogonadismo - Revisione Basata sull'Evidenza
Product Description Enclomisign is a novel, non-invasive medical device designed for the treatment of moderate, androgen-deficient hypogonadism in adult males. It operates on the principle of targeted photobiomodulation (PBM), delivering specific wavelengths of near-infrared (NIR) light to the scrotal tissue. Unlike traditional testosterone replacement therapy (TRT), which introduces exogenous hormones, Enclomisign aims to stimulate the body’s own endogenous testosterone production by enhancing mitochondrial function and cellular energy (ATP) production within Leydig cells.
Enclomisign: Stimulating Endogenous Testosterone for Hypogonadism - Evidence-Based Review
Product Description: Enclomisign is a novel, non-hormonal oral compound classified as a selective estrogen receptor modulator (SERM) with a unique profile. It is being developed and studied primarily as a potential therapeutic agent for the management of male hypogonadism, specifically aiming to increase endogenous testosterone production without the typical suppression of the hypothalamic-pituitary-gonadal (HPG) axis associated with exogenous testosterone or the estrogenic side effects of classic SERMs like clomiphene citrate. Its core mechanism revolves around antagonizing estrogen receptors in the hypothalamus, thereby blocking the negative feedback of estrogen and stimulating the pulsatile release of gonadotropin-releasing hormone (GnRH), followed by luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary.
Enclomisign
$99